Expert Perspectives on the Evolving SGLT Inhibition Treatment Landscape

  • Saturday, September 28, 2024
  • 7:15 pm - 8:15 pm ET
  • Room: Triumph E
  • Signia Hotel Atlanta | Atlanta, Georgia
  • CME/CNE/CPE
  • Hybrid
Overview


This satellite symposium, held in conjunction with the 2024 Heart Failure Society of America (HFSA) Annual Meeting, has been indefinitely postponed due to the current forecast for the Atlanta, Georgia area. This cancellation includes the virtual program.

We will reach out to all registered attendees to confirm the new event date as soon as possible. We appreciate your patience and understanding and we look forward to seeing you at another Medscape event in the near future.

Speakers
Speaker Image
Zachary Cox, PharmD
Chairperson

Professor of Pharmacy

Lipscomb University College of Pharmacy

Nashville, TN

Speaker Image
Biykem Bozkurt, MD, PhD

The Mary and Gordon Cain Chair in Cardiology

Professor of Medicine

Senior Dean of Faculty, Baylor College of Medicine

Director, Winters Center for Heart Failure Research

Associate Director, Cardiovascular Research Institute

Baylor College of Medicine

Houston, TX

Speaker Image
Ileana Piña, MD, MPH

The Robert Stein Chair of Quality and Safety for the Cardiovascular Service Line

Professor of Medicine

Cardiology, Heart Failure/Transplant

Sidney Kimmel Medical College at Thomas Jefferson University

Philadelphia, PA

Agenda

7:15 pm

Welcome and Introductions

Chairperson, Zachary Cox, PharmD

7:20 pm

Presentations:

  • Understanding SGLT Inhibition and HF

    Biykem Bozkurt, MD, PhD

  • Digging Deep Into the Clinical Safety and Efficacy of SGLT Inhibition

    Zachary Cox, PharmD

  • Practical Considerations for SGLT Inhibition in HF

    Ileana L Piña, MD, MPH

8:05 PM

Panel Discussion and Q&A

159 Northside Dr NW, Room: Triumph E, Atlanta, Georgia, 30313
Get Directions
Program Information
Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Accreditation logos
Accreditation logos
For Physicians

Medscape, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-24-216-L01-P).

Learning Objectives

Upon completion of this activity, participants will:

Have increased knowledge regarding the:

  • Role of SGLT inhibition in the care of patients with HF
  • Latest clinical safety and efficacy data for SGLT inhibition in patients with HF
  • Economic impact of SGLT inhibition in the care of patients with HF

Have greater competence related to

  • Appropriate SGLT inhibition in patients across the spectrum of HF
Goal Statement
The goal of this activity is for learners to be better able to identify the role of SGLT inhibition in HF prevention and treatment; evaluate the latest clinical safety, efficacy, and cost-effectiveness evidence for the use of SGLT inhibition in patients with HF; define practical considerations for SGLT inhibition in patients with HF; and understand how to implement guideline-directed medical therapy (GDMT) with SGLT inhibition in individual treatment plans in accordance with the latest clinical evidence and guideline recommendations.
Target Audience
This activity is intended for cardiologists, primary care physicians, emergency medicine physicians, diabetologists/endocrinologists, nurse practitioners, nurses, physician assistants, and pharmacists.